Abstract: Disclosed are, among other methods, methods for reactivating retinal ganglion cells in mammals by administering an effective amount of channelrhodopsins (such as ChrimsonR), or an effective amount of such channelrhodopsins (such as ChrimsonR) fused to a fluorescent protein, in the form of protein or nucleic acids, and compositions thereof. The methods may include a light stimuli level inducing RGCs response that is below radiation safety limit. The methods may include delivery by an adenoassociated virus vector. The methods may include use of a CAG promoter. The methods may result in a long term expression of an effective amount of the channelrhodopsins (such as ChrimsonR protein).

Abstract: The invention is directed to the therapeutic use of arylsulfonamide derivatives.

Abstract: The present invention relates to novel N-(phenylsulphonyl)glycyl-glycine compounds, which are defined by formula I and the description, as well as their method of preparation and their use in therapeutics 1

Abstract: The present invention relates to novel compounds which inhibit the action of CXC chemokines, such as IL-8, Gro, NAP-2, ENA-78 etc., on their receptors, to the process for their preparation and to their use for obtaining drugs. According to the invention, said compounds are novel indole derivatives selected from the group consisting of: i) the products of the formula  in which: X is a double bond —C═C— or a sulfur atom; R1 is a halogen, a nitro group, a trifluoromethyl group or a C1-C3 alkyl group; R2, R3 and R4 are each independently a hydrogen atom, a halogen, a C1-C3 alkyl group, a nitro group, a trifluoromethyl group or a cyano group, or R2 and R3 form a fused aromatic ring together with the aromatic ring to which they are attached; and n is equal to 2 or 3; and ii) esters of the compounds of formula I and addition salts of said compounds with a mineral or organic base.

Abstract: The present invention relates to novel compounds of the formula in which:X is a halogen atom,R.sub.1 and R.sub.2, which are identical or different, are each --H or --A--B--R.sub.3,A is a linear or branched C.sub.1 -C.sub.12 -alkylene chain,B is a single bond, a divalent phenylene group or a divalent indolyl group of the structure ##STR1## R.sub.3 is --H, --OH, --NR.sub.4 R.sub.5 or --COR.sub.6, R.sub.6 is --OH, --OCH.sub.3, --OC.sub.2 H.sub.5 or --NR.sub.4 R.sub.5,R.sub.4 and R.sub.5, which are identical or different, are each H, a C.sub.1 -C.sub.4 -alkyl group, --(CH.sub.2).sub.n --OH, --(CH.sub.2).sub.n --N(CH.sub.3).sub.2 or --CO--CH.sub.3, andn is an integer with a value of 2, 3 or 4; and their addition salts. It further relates to their preparation and to their use in therapeutics, especially for the treatment of pathological conditions involving bradykinin.

Abstract: The present invention relates to novel asymmetrical esters derived from 1,4-dihydropyridine-3,5-dicarboxylic acid, of the formula: ##STR1## in which: R.sub.1 represents a C.sub.1 -C.sub.4 alkyl group, R.sub.2 represents a C.sub.1 -C.sub.4 alkyl group, a benzyl group, a benzoyl group or a phenyl group optionally substituted by one or more C.sub.1 -C.sub.4 alkoxy, C.sub.1 -C.sub.4 alkyl, cyano, nitro, hydroxyl or trifluoromethyl groups or by one or more halogen atoms, and R.sub.3 and R.sub.4, which are identical or different, each represent the hydrogen atom, a nitro group or a chlorine atom,their optical isomers and diastereoisomers and also the corresponding addition salts.These novel esters are useful in therapy, especially as antihypertensives.

Abstract: The present invention relates to novel asymmetrical esters derived from 1,4-dihydrophyridine-3,5-dicarboxylic acid, of the formula: ##STR1## in which: R.sub.1 represents a C.sub.1 -C.sub.4 alkyl group, R.sub.2 represents a C.sub.1 -C.sub.4 alkyl group, a benzyl group, a benzoyl group or a phenyl group optionally substituted by one or more C.sub.1 -C.sub.4 alkoxy, C.sub.1 -C.sub.4 alkyl, cyano, nitro, hydroxyl or trifluoromethyl groups or by one or more halogen atoms, and R.sub.3 and R.sub.4, which are identical or different, each represent the hydrogen atom, a nitro group or a chlorine atom, their optical isomers and diastereoisomers and also the corresponding addition salts.These novel esters are useful in therapy, especially as antihypertensives.

Abstract: The present invention relates to new asymmetric heterocyclic ester derivatives of 1,4-dihydropyridine-3,5-dicarboxylic acids of the formula: ##STR1## wherein R.sub.1 is a C.sub.1 -C.sub.4 -alkyl group; X and Y, which are identical or different, each represent O or S, at least one of the symbols X and Y being different from S; n is an integer equal to 1 or 2; and R.sub.2 and R.sub.3, which are identical or different, each represent H, CH.sub.3, CF.sub.3, C.sub.6 H.sub.5 or halogenophenyl, it being possible for R.sub.2 and R.sub.3, taken together, to form a 5-membered to 7-membered spirocycloaliphatic group with the C atom of the heterocyclic group to which they are bonded; and their optical iomers and diastereoisomers.These new derivatives are useful as pharmaceuticals, in particular as vasodilators.